title: [Pharmacological treatment of hereditary haemorrhagic telangiectasia].
abstract: Hereditary hemorrhagic telangiectasia (HHT) of Rendu-Osler-Weber disease is a multi system vascular dysplasia characterized by the presence of multiple telangiectasias, mainly affecting mucosal tissue and arterial-venous connections. It commonly affects lungs, liver and central nervous system. Bleeding is the most common symptom and its treatment can be surgical or pharmacological. We herein review the systemic therapy that attempts to minimize bleeding as well as blood transfusion therapy. Blood therapy and fibrinolytic treatment especially aminocaproic acid and tranexamic acid are discussed. Danazol, hormone therapy and other less common drugs used in the treatment of HHT are also reviewed.
authors.affiliation: Servicio de Medicina Interna, Hospital da Barbanza, Riveira. A Coruña, España.
authors.forename: Sonia
authors.initials: S
authors.lastname: Molinos-Castro
authors.forename: Paula María
authors.initials: PM
authors.lastname: Pesqueira-Fontán
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Díaz-Peromingo
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001803:Blood Transfusion; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000628:therapy*; D014148:Tranexamic Acid / Q000627:therapeutic use
chemical_list: D000933:Antifibrinolytic Agents; D006728:Hormones; D014148:Tranexamic Acid